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The "differentiation antigens", Ly 1 and Ly 2, present on thymus cells and thymus- 
derived lymphocytes (T  cells)  1 of mice  (1)  have  been  shown  to  mark  differentiated 
functional subpopulations of normal peripheral T cells. By using cytotoxic elimination 
experiments, it was reported initially that in C57BI.J6  (B6) mice, an Ly 1  + Ly 2-  (Ly 
1 ~,  Ly 2 $ )2 subpopulation of peripheral T  cells primed with sheep erythrocytes had 
helper activity for an in vitro sensitized trinitrophenol-specific antibody response; while 
among T cells of B6 mice immunized with cells allogeneic to B6, only those bearing the 
Ly 2 phenotype had killer activity in vitro against a fibroblast target of the same allotype 
as the cells used for immunization (2). In an expanded study, the Ly 1-2+3  + (Ly 1 J,, Ly 
2,3 J' ) phenotype of cytotoxic effector cells was confirmed in B6 mice, which express the 
Ly 1.2, 2.2, 3.2 alleles. However, in B6/Ly 1.1  congenic mice which express the Ly 1.1, 
2.2,  3.2  alleles (i.e.,  the congenic strain  of mice in which the  Ly 1.2  allele has been 
replaced by the Ly 1.1  allele) Ly 1+2+3  + cells also were demonstrated to be cytotoxic 
effector cells  (3). Moreover,  T  cells  which  are  precursors  of killer  or  helper  cells 
apparently are differentiated for these Ly antigens before immunization (4), although 
the point at which this differentiation takes place has not been ascertained. Also under 
certain experimental conditions T cells, expressing the Ly 1-2  + phenotype, are required 
for immune suppression (5). These initial observations of functional subsets with specific 
restricted Ly phenotypes have been confirmed, and extended to encompass a variety ofT- 
cell functions (6-19). 
Tumors with differentiated T-cell phenotypes would be potentially valuable 
for studies of T-cell function. Most T lymphocytic tumors in the mouse however, 
are spontaneous and induced tumors of thymic origin. The thymus is thought to 
be chiefly a lymphocytopoietic tissue containing relatively immature cell types. 
The original report in which Ly 1 and Ly 2 antigens were described (1) indicated 
that lymphomas varied in the expression of Ly antigens,  although it was not 
reported whether the tumors expressed both Ly specificities when positive. That 
* Supported by the Cancer Research Institute,  New York. 
'Abbreviations  used in this  paper: ABS,  absorption; B6,  C57BL/6;  C,  complement;  CT, 
cytotoxicity;  ENU, 1-ethyl-1  nitrosourea;  FI-GAMIg or (heavy chain),  fluorescent  goat anti-mouse 
Ig  or (Ig  heavy chain);  IF, immunofluorescence; T cells,  thymus-derived lymphocytes; TL, thymus 
leukemia antigen. 
2  The +/-  superscript nomenclature  is a simplification of the conclusion from the original 
papers (2, 3) on functional subsets,  one of  which (3),  suggested the Ly I  $ :Ly 2,3 I' (i.  e., arrows) 
nomenclature  to indicate that the functional populations were relatively poor or rich in the 
respective antigens. 
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report also noted that the expression of TL, another T-cell antigen (20), was not 
correlated with the presence or absence of Ly antigen. Several questions about 
the phenotypic expression of Ly on neoplastic cells  are  not resolved:  (a)  Are 
both Ly 1 and Ly 2 antigens expressed equally on all T-cell tumors, or are the 
T-cell tumors, like peripheral T cells, differentiated for Ly phenotype?; (b) Are 
Ly antigens expressed only on T-cell lymphomas?, and (c) What is the relation 
of the antigenic phenotype to cell differentiation and leukemogenesis? To study 
these  questions,  we  have  examined  early  transplantation  generations  of a 
number of BALB/c lymphoid tumors induced by 1-ethyl-l-nitrosourea as well as 
early  transplantation generations of spontaneous AKR lymphomas,  for Ly  1, 
Ly 2, TL, and Thy 1 phenotypes. 
Materials and Methods 
Mice.  Mice used in these experiments for tumor passage were either BALB/c AnN, bred at 
the Animal Production Unit, National Institutes of Health, Bethesda, Md. or by Litton Bionetics, 
Kensington, Md., or AKR/J from The Jackson Laboratory, Bar Harbor, Maine. 
Mice congenic with B6 were used for specificity  controls  with Ly and TL antisera,  and were 
either obtained directly  from Dr. E. A. Boyse, Memorial Sloan Kettering Cancer Center, New 
York, or  bred in this  Laboratory from stock obtained from Dr. Boyse. These congenic stocks  are 
designated B6/Ly 1.1, B6/Ly 2.1,  Ly 3.1, and B6/TL  + following the simplified  nomenclature of 
Shiku et al. (3).  A/Thy i  .1 mice congenic with A strain mice, but expressing the Thy 1.1 rather 
than the Thy 1.2 antigen, were obtained from Dr. David Sachs, National Cancer Institute,  for 
specificity  controls  with Thy 1 antisera. 
Tumor Induction and Transplantation.  Specific  tumor designations with further information 
for  BALB/c tumors are  shown in  Table I.  P1798, a long-term passage tumor line  arose in  a BALB/ 
c mouse treated with estrogen (21).  All of  the other BALB/c tumors presented here are of  recent 
origin and most were tested  at less  than 10 transplantation generations. These tumors were 
induced  by  2 intraperitoneal  injections  of  1-ethyl-l-nitrosourea  (ENU), I  wk apart in  1-  to  2-too  old 
animals.  Each injection  contained  I pmol ENU/g body weight. The ENU  was prepared and 
injected  by Dr. Jerry Rice,  National Cancer Institute.  Some of  the tumors arose in ENU-treated 
mice that were subsequently given a single i.p.  injection  of  pristane (2, 6, 10, 14 tetramethyl 
pentadecane) 1 mo later  (22).  Eight of  the BALB/c tumors presented as primary thymic tumors 
with or without evidence  of generalized spread of the leukemic process while two of them 
BALENTL  13 and 14 arose as generalized leukemias. The BALB/c tumors were transplanted by 
serial  i.p.  or s.c.  passage. Solid  tumor tissue  was minced into  suspension, or peritoneal tumor 
ascites  cells  were used when available for  the tests  performed. 
The AKR  transplantable tumors, AKRLS-12, AKRLS-13, and  AKRLS-34, were initiated  by s.c. 
or i.p.  transplantation of primary spontaneous thymic tumors of  AKR/J mice >  4 mo of age. 
Pathology of  these tumors was  judged only on a gross level  and was comparable to  the  frequently 
described pattern of  lymphoid tumors for  this  strain  of  mice: grossly  enlarged thymus; enlarged 
lymph nodes; and enlarged spleen in some cases.  The only selective  basis for inclusion in this 
study was the availability  of early transplantation generations (generations 5-11).  All of the 
tumors have been  frozen  in liquid  N2. Six  recovered lines  were tested  including BALENTL  13, 14, 
P1798, and the 3 AKR  tumors. 
Antisera.  Anti-Ly, -TL, and -Thy 1 antisera  which were similar  to  those previously described 
(3),  were a generous  gift  of  Doctors E.  A. Boyse and F-W. Shen, Memorial Sloan-Kettering Cancer 
Center, and are  listed  below (Table H). The antisera were selected  for  specificity  of  reaction  only 
on thymocytes of B6 or the appropriate congenic strain.  When necessary these antisera were 
absorbed with normal thymus and peripheral lymphoid tissue  or  tumors of  the  opposite  allelic  Ly 
specificity.  The titers  and dilutions  of  the antisera also  are indicated in Table If. 
Cytotoxieity  Test.  The cytotoxicity  (CT) test  of  Gorer and O'Gorman (23)  was used with the 
modifications described by Boyse et al. (24).  Equal 0.05-ml vol of (a) antiserum serially  diluted; 
(b) selected  rabbit serum, diluted 1:15,  in Ly tests  (25,  26),  or  selected  guinea pig serum, diluted 
1:4,  in  TL and Thy 1  tests  (both  complement [C]  sources were selected  for  low  cytotoxicity  against B.  J.  MATHIESON,  P.  S.  CAMPBELL,  M.  POTTER, 
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Name  Induction  Days  $ 
Pathology 
Gross§  Microscopi¢l 
Transplanta- 
tion  genera- 
tions  tested¶ 
BALENTL 3  ENU  132  T  S-LN,  Thymus  3, 4 
BALENTL 4  155  T  -  3¶ 
BALENTL 5  173  T  L-LN, Viscera  2,  3,  6, 15, 17 
BALENTL 6  273  T  S-LN, Thymus  I,  2 
BALENTL 7  ENU + Pristane  273  T  -  1¶ 
BALENTL 8  311  T  S-LN,  Thymus  1,3 
BALENTL 9  344  G  S-LN,  Thymus, early spleen  3¶ 
BALENTL 13  145  G  S-LN, Lymph node; RCS-B,  3, 4,¶ 5,4 12 
Liver 
BALENTL 14  ENU  443**  G  L-LN,  Viscera  4,4 12 
P1798  Estrogen pellet  521"*  T  S-LN,  Thymus  189, 193, 194 
BALENLM 11  ENU  260  G  S-LN, Lymph node, spleen  2, 3, 4, 7, 10 
(non.thymic) 
BALENLM  15  ENU + Pristane  227  -  Giant cell  sarcoma  i¶ 
BALENLM  16  173  -  Microscopic  plasma  cell  tumor  1¶ 
BALENLM  17  235  G  S-LN (Mastocytoma)$*  1,¶  2 
*All  of  these  tumors  were  induced  in BALB/c AnN mice+ 
SDays  after  treatment  with  ENU. 
iT,  thymic,  G, generalized  lymphoma. 
I]S-LN, small cell lymphocytic  neoplasia;  L-LN, large cell lymphocytic  neoplasia;  RCS-B, Dunn reticulum cell sarcoma type B. 
¶A  number  of  these  tumors  were  tested  from  more  than  one  animal at  the  same  transplantation  generation.  The  transplantation 
generation  number indicates  the  number of  times  the  tumor  was  transplanted  prior  to  testing, 
**Actual  age  of  mouse in  days. 
$$This  tumor initially  appeared  to  be mixed  for  cell  type,  but  grew  out  as  a mastocytoma on  transplantation. 
TABLE  II 
Antisera* 
Specificity  Immunization  Test  Thymocytes  Maximal CT  Titer 
Anti-Ly 1.1  (BALB/c x B0)F, vs. B6/Ly 1.1 thymocytes  B6/Ly 1.1  >95%, 1/160  2,000 
Anti-Ly 1.2  C3H/An vs. CE thymocytes  B0, BALB/c, AKR  >95%, 1/80  320 
Anti-Ly 2.1  BT/H-2  k vs. CE thymocytes  B6/Ly 2.1, 3.1, AKR  >90%, 1/84)  640 
Anti-Ly 2.2  (C3H/An x B6/Ly 2.1)F~ vs. ERLD*  B6, BALB/c  >90%, 1/80  320 
Anti-TL  (B6 x A/TL-)F, vs. ASL1  BALB/c  70%, 1/200  1,000 
A, B6/TL  +  >95%, 1/400  6,400 
Anti-Thy I.I  (B6 x A)F,  vs.  A/Thy 1.I thymocytes  A/Thy 1.1,  AKR  >95%, 1/80  2,000 
Anti-Thy 1.2  (A/Thy  1.1 x AKR/H-2~)F~ vs.  ASLI*  A, BALB/c  >95%, 1/500  5,000 
*The maximal cytotoxicity  is given as the percent dead cells at the serum dilution indicated. The titer is the reciprocal of the 
dilution which gives 50% lysis on the cells indicated. 
SERLD and ASL1 are B0 and A strain tumors, respectively, which have long transplantation histories. 
mouse  thymocytes  and  high  C  activity); and  (c) cells suspended  in Medium  199 with Hanks' 
balanced salt solution (5 x  106 cells/ml) were incubated for  45 min at  37°C. The data are presented 
as percent dead (stained) cells after the addition of  trypan blue in 0.15 M  saline. 
Immunofluorescent Reagents.  Goat anti-mouse Ig heavy chain and anti-mouse pelyvalent Ig 
antibodies were prepared by affinity chromatography and tested as described elsewhere (27). 
Goat  antibodies were  coupled  to  fluorescein by  reaction with fluorescein isothiocyanate to 
achieve a  molar fluorescein: protein ratio of 2.5-5.7.  Unconjugated fluorescein was removed by 
passage over Sephadex G-25 equilibrated with 0.01 M  phosphate buffer in 0.15 M  NaC1,  pH 7.4. 
These fluorescent reagents are  designated F1-GAM  (heavy chain) and  FI-GAMIg.  All of these 
reagents react with <1% of normal thymocytes. 
Immunofluorescence  Test.  The  immunofluorescence (IF) test of MSller  (28)  was adapted as 
follows for  use  with  mouse  alloantisera. Equal  vol  (0.05  ml)  of diluted alloantisera and  cells 
prepared in Hanks' medium with 10% heat inactivated fetal calf serum and 0.1% sodium azide (20 
×  106  cells/ml) were  mixed on  ice for  30 min.  The  suspensions were then diluted to  2  ml and 
washed twice with centrifugation at 220 g. Appropriate F1-GAM (heavy chain) or F1-GAMIg (0.05 1270  EXPRESSION  OF  Ly  ON  MOUSE  LYMPHOMAS 
ml), diluted to 0.5 mg/ml protein in phosphate-buffered  saline was added to the pellet. The cells 
were suspended  and incubated on ice again for 30 rain and washed  as before. The washed cell 
pellets were  suspended  in  1-drop vol  and put  on  slides with cover  slips and read under oil 
immersion with a Leitz fluorescent scope with Ploem illuminator (HBO 100W/2 mercury lamp 
with BG38 and BG12 excitation filters and an $546 barrier filter). 
The use of the F1-GAM~/z  reagent allowed us to type Ig  +, H chain- tumors for Ly phenotype as 
discussed below. (See Results) 
Absorption Tests.  Tumors or normal lymphoid tissues for controls were prepared by suspen- 
sion in Medium 199 with Hanks' balanced salt solution. The cells were washed twice, resuspended 
in 3-5-ml vol, and enough cells to yield a 0.05-ml cell pellet were dispersed into 50 x 6-mm tubes. 
Ai~r centrifugation at 800 g the supernate was aspirated and a 0.11-ml of appropriately  diluted 
antiserum was added and mixed with the cells. The dilution of antiserum used in these tests was 
determined previously  to be a dilution at which maximum positive reaction (either 90-95% CT or 
>90% IF) was observed on the appropriate thymus test cels. The absorptions (ABS) were carried 
out by mixing the cells on ice for 45 rain, centrifuging the absorbing cells into a pellet, and 
transferring the absorbed serum supernate to a fresh tube for either a standard CT assay with 
serial twofold dilutions or IF on an antigen-positive thymus cell. This is the most critical test 
because  antiserum specificity can be completely controlled by the use of B6 or congenic mouse 
thymocytes as the positive test cell after the absorption. Positive (+) ABS is indicated when no 
reactivity above complement controls or <1% IF was observed on the positive test cells. Negative 
(-) ABS indicates that no reduction was observed greater than that obtained with negative 
control, lymphoid tissue of mice with the opposite Ly (Thy 1 or TL) allele. Usually this does not 
exceed 5-10%. Exceptions are noted in the Tables. 
Results 
Preferential Expression  of Either Ly 1  or Ly 2  on Lymphoma  Cells.  Table 
HI presents a  summary of the CT, IF, and absorption data for the BALB/c and 
AKR tumors. 11 of these tumors were tested by all three tests. All of the tumors 
were tested at least twice and some of the tumors were tested a number of times 
(see Table I  and below). 
CT Tests on BALB/c Tumors.  Typical CT data for two of the tumors tested 
with  anti-Ly  1.2  and  anti-Ly 2.2  are  present  in  Fig.  1.  A  high  level  of CT 
>90% at the 1/80 dilution of anti-Ly 1.2  was observed for BALENTL 13,  while 
CT for BALENTL 5 was 28%  under the same conditions. CT  with anti-Ly 2.2 
indicated that BALENTL 5 cells were >90% positive (BALENTL 13  CT under 
the  same  conditions was  <10%).  The  initial dilutions of both  antisera were 
chosen to be on a  maximum plateau of kill for normal BALB/c thymocytes. In 
Table III the CT data for these tumors and other similar tumors are presented 
in summary at this plateau dilution. It is evident that some of these tumors had 
high levels of expression of either Ly 1 or Ly 2 antigen, indicated as Ly 1  + or 
Ly 2 +, comparable to the Ly phenotypic expression of normal thymus cells, but 
clearly both antigens were not expressed to the same degree. With these criteria 
BALENTL 3-8  and  14  are  Ly  1-2  +  and  BALENTL  13  is  Ly  1+2 -,  It  also is 
evident that two of the BALB/c lines, P  1798 and BALENTL 9 were positive for 
both Ly antigens. The level of CT, however, was lower for both of these tumors 
compared to normal thymocytes. 
CT  results  on  tumor  cells prepared from  lymphoid or  solid tumor  tissues 
suggested that some of the tumors which were scored as negative for one of the 
Ly antigens had a  subpopulation of about 15% positive cells. This low degree of 
positive reactivity was absent in ascites tumors. 
Occasionally these tumors were tested with antisera to Ly 1.1  or Ly 2.1, the B.  J.  MATHIESON,  P.  S.  CAMPBELL,  M.  POTTER,  AND  R.  ASOFSKY  1271 
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Fzo.  1.  Cytotoxicity of anti-Ly  1.2  and  anti-Ly  2.2  on  BALENTL  13  and  BALENTL  5. 
Cytotoxicity  =  percent  dead  cells  (stained  with  trypan  blue)  on  ordinate;  1/dilution  of 
antiserum on abscissa.  BALENTL 13 was tested at generation 5 in ascites form (See Table 
VI) and BALENTL  5  was tested at generation  2  as a  suspension  of a  solid subcutaneous 
tumor. Control normal BALB/c thymus cells were obtained from a  2-too old animal. Serum 
controls  (serum  1:80,  without  C  added,  not  pictured)  were  <10%  for both  antisera  with 
either tumor. 
opposite alleles to those detected on BALB/c cells, and no positive tumors were 
observed with either antiserum. 
BALENLM  11,  15,  and  17 tumor cell  suspensions  had reduced phenotypic 
expression of both Ly 1 and Ly 2 antigens and were also Thy 1.2- and TL-. 
IF Assay of Ly Antigen Expression.  Because  CT tests as performed here 
with anti-Ly sera cannot distinguish with satisfaction reactions on subpopula- 
tions  of cells,  we  developed  immunofluorescence  tests  for  use  with  mouse 
alloantisera.  This approach had the potential of asking whether tumors with 
low antigen expression by CT, e.g., 20% had (a) reduced antigen expression on 
all  the  tumor  cells  thus  reducing  the  sensitivity  of the  cells  to  lysis  with 
antibody  and  C,  or  (b)  a  minor  subpopulation  of positive  cells  with normal 
thymus levels of Ly antigen expression. 
With these high CT anti-Ly sera, either F1-GAMIg or F1-GAMT2 reagent was 
satisfactory for IF tests on normal thymus cells, because the maximum number 
of Ly  ÷  cells  were  labeled  with  either  reagent.  However,  the  fluorescence 
intensity of the F1-GAM72 was lower and therefore the F1-GAMIg reagent was 
employed  whenever  possible.  When  tested,  F1-GAMT1, F1-GAMIgA,  and  F1- 
GAMIgM did not give satisfactory stains with these anti-Ly sera. The specificity 
of the  sera  used  in  this  report  was  confirmed  by  tests  on  the  appropriate 
congenic thymocytes. Under the conditions described, fluorescent dots on >90% 
of the cells could be seen when the sera had been selected and/or absorbed  to 
react specifically with thymocytes from B6 or the proper  Ly congenic strain. 
Since the F1-GAMT2 reagent reacts with <1% of spleen cells and  <5% of Ig  + 
tumor cells, this reagent, when used with anti-Ly sera, allowed us to test Ig  + 1272  EXPRESSION  OF  Ly  ON  MOUSE  LYMPHOMAS 
TABLE  III 
Antigen Distribution on BALB/c and AKR Tumors* 
Tumor 
Ly 1.2  Ly 2~  TL  Thy  1~: 
CT  IF  ABS  CT  IF  ABS  CT  IF  ABS  CT  ABS 
BALENTL  3  <5  95  >90 
BALENTL  4  20  90  95 
BALENTL  5§  21  II  -  >90  >90  +  >95  72 
BALENTL  6  14  <5  -  52  >95  +  >95  95 
BALENTL  7  15  -  95  + 
BALENTL  8  <10  -  36  >95  +  >90 
BALENTL  9  31  >95  +  50  >95  +  76  >95 
BALENTL  13§  90  90  +  10  <5  <10  <10 
BALENTL  14  <1-20  -  58-90  +  >90  >9{) 
P  1798  50  50  +  27  9Q  +  >95  >95 
BALENLM  11¶  (-)  27  (-)  22  (-)  1 
BALENLM  15  28  <5  28  <5  <5 
BALENLM  16¶  <5  13  <5 
BALENLM  17  24  Ii  -  4  <5  <i0  <i 
AKR LS 12  >90  <I0  <5 
AKR LS 13  <5  <5  -  51  90  +  <5  <1 
AKR LS 34  21  <1  -**  42  95  +  21  <5 
98 
+  >95  + 
+  + 
+  (6o%)11 
+  51  + 
+  76  + 
-  34  + 
+  >95  + 
+  43  + 
16  + 
<10 
-  <5 
-  23  + 
-  17  + 
*CT, percent dead (trypan blue stained)  cells.  CT data are presented at the 1/80  dilution  for anti-Ly 1.2,  1/40  or 1/80  for anti-Ly 
2.2, 1/200  for  anti-TL, 1/500  for  anti-Thy 1.2,  1/40  for  anti-Ly 2.1 and 1/80  for  anti-Thy 1.1.  IF, percent fluoresoent  celia Antisera 
to Ly 1, Ly 2, and TL were routinely treed  one twofold dilution  less  than indicated for CT tests.  Control cell  l~rel~rations  incu- 
bated with FI-GAMIg were routinely <5% except for  BALENLM  1  i, 15, 16,  and 17,  which were 37->95% Ig* but  which were < 1% 
positive  with FI-GAM~I. ABS (absorption data) are summarized as: positive  ABS (+), <1% IF (or <5% CT) on peaitive  indicator 
cells.  Negative ABS (-),  90-95% IF or CT on peeitive  indicator  cells.  B6 or B6/Ly congenic thymocytos were usod for  testing  ab- 
sorbed anti-Ly sara,  BALB/c thymus cells  were used for  testing  absorbed anti-TL, and A/J or A/Thy 1.1 thymus cells  were used 
for testing absorbed anti-Thy I. C controls on tumors were about 10% (5-10)  in most cases. 
SThe Ly 2.2 and Thy 1.2  alleles  are expressed on normal BALB/c thymocytes and BALENTL  lymphomas. The Ly 2.1 and Thy i.1 
alleles  are expressed on AKRLS  lymphomas and normal AKR  thymocytes. 
}More detailed data are presented for BALENTL  5 and BALENTL  13 in Tables IV and V. 
llThis tumor absorbed  60~ of the anti-Thy  1.2 CT compared to complete  absorption with an equal volume of normal packed 
BALB/c thymus cells. 
~CT results  were not greater than controls  15-20% dead cells,  however, cell  loss  during the test  incubation was a mzdor problem 
with BALENLM  11 as well as for BALENLM  18. 
**Under the conditions described, partial  absorption of  30% was observed. This low degree of  absorption was assumed to be from 
contaminating host cells  (see  text). 
tumors for Ly antigen. For tests of Ig  + tumors, the Ly sera were centrifuged at 
100,000 g  for 20 min in a  Beckman Airfuge (Beckman Instruments, Fullerton, 
Calif.) to remove immunoglobulin complexes and aggregates. 
When lymphoid tumors (BALENTL 3, 5, 6, 8, 13, and 14) were tested by IF for 
Ly expression and when only large or intermediate sized cells (i.e., presumptive 
tumor cells) were scored for fluorescence, the tumor cells consistently appeared 
to be totally negative for one of the Ly antigens and strongly positive for the 
other. The pattern of surface dots with anti-Ly sera and F1-GAMIg was quite 
distinct and was similar on normal thymus and tumor cells. The question of low 
positive reactions was clarified by IF tests since a subpopulation of smaller cells 
was observed with brightly fluorescent dots, probably indicating a contaminat- 
ing host cell population rather than a  low level of antigen expression on the 
total population of tumor cells. 
Lack  of Ly on Ig ÷ Tumors.  Initial attempts to type several of the BALB/c 
tumors by cytotoxicity tests were unsatisfactory because of a  depletion of test 
cells during the 37°C incubation with C. When BALENLM 11, 15, 16, 17, were 
tested  for  surface  Ig  by  IF  with  polyvalent  F1-GAMIg,  a  clear  pattern  of 
fluorescent membrane dots and rims was observed. This suggested that these 
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surface Ig  + tumors were subsequently tested for Ly and TL antigens by IF with 
F1-GAM~2. In these tests, where loss of tumor cell was not a  problem, the F1- 
GAM~/2-negative tumors were also negative with either anti-Ly 1.2 or anti-Ly 
2.2 sera.  Preliminary tests of ABLS 5,  PL 1,  and PL 2,  Abelson virus-induced 
tumors, also indicate a lack of Ly antigens on these tumors (M. Potter and B. J. 
Mathieson, unpublished data). 
Expression  of TL and  Thy 1.2 Antigens  on BALB/c Tumors.  Two  of the 
tumors,  P  1798 and BALENTL 9,  undifferentiated for the T-cell markers Ly 1 
and  Ly 2,  similar  to  normal  thymus  cells,  are  TL  +.  In  addition  most  of the 
BALB/c tumors with a single Ly phenotype also express TL. On at least two of 
the Ly 2  + TL  + tumors,  BALENTL 5 and 6, the TL specificities observed are at 
least TL.2 and TL.1, 4 or 5 (20,  29); and TL.3 is not expressed in addition to the 
normal TL.2 specificity. This conclusion is drawn from the following observa- 
tions:  anti-TL serum absorbed with either BALENTL 5 or 6 remains cytotoxic 
on either A  strain  or B6/TL  + thymocytes but not on BALB/c thymocytes, and 
anti-TL  serum  absorbed  with  ERLD,  a  TL.1,  2,  4  positive  tumor,  removes 
cytotoxic reactivity to the BALENTL tumors. 
Most of the tumors were tested for Thy 1.  CT with anti-Thy  1 sera is often 
greatly  reduced  on  tumors  but  maximal  CT  of 95%  could be  obtained  with 
increased serum concentrations. Only the T-cell tumors tested, i.e., tumors that 
were Thy 1  ÷ and/or TL  ÷, express Ly antigens,  while several non-T-cell tumors 
do not. 
Absorption  Tests for T-Cell Antigens.  Since CT and IF tests are direct tests 
on tumors, it was necessary to confnnn the tumor cell phenotypes by absorbing 
known  positive  sera  with  tumor  cells  under  experimental  conditions  which 
would  allow  maximum  sensitivity,  and  then  testing  the  absorbed  sera  on 
positive indicator normal thymocytes to check for specific ABS. The summary 
table  (Table  III)  indicates  those tumors  which  were tested  by ABS and  the 
results  completely agree  with the  phenotypes determined  by CT  and  IF.  On 
some of the tumors, the phenotype was confirmed for all of the T-cell antigens by 
ABS tests. 
Stability of Surface  Phenotype  in BALB/c T-Cell Lymphomas.  The surface 
phenotype is stable over a  number of generations,  as demonstrated by BAL- 
ENTL 13, an Ly 1.2 +, 2.2- tumor (Table IV) and BALENTL 5, an Ly 1.2-, 2.2  + 
tumor  (Table  V).  Repeated  tests  on  BALENTL  13  indicated  an  Ly  1+2 - 
phenotype in two sublines and on different tumor cell sources within  a  single 
transplant host. The isolated observation of a substantial Ly 2  + population in a 
solid peritoneal tumor mass was not repeated when tested several generations 
later and remains unexplained. 
AKR  Tumors,  Transplanted  AKR  Thy  1.1 ÷  lymphomas  (AKRLS  12,  13, 
34)  also  appear  to  have  restricted  expression  of  Ly  antigens  (Table  III). 
Preliminary  data  (not  shown)  from  an  additional  group  of  AKR  thymic 
lymphomas have indicated that the one notable difference between these tumors 
and BALB/c tumors is the low incidence ofTL  ÷ AKR tumors, which is consistent 
with previously reported data for lymphomas of this strain (20). Nearly all (9 of 
10) of the BALB/c T  cell tumors and 0 of 3 of the AKR tumors presented here 
are TL  ÷. 1274  EXPRESSION  OF  Ly  ON  MOUSE  LYMPHOMAS 
TABLE IV 
Ly Antigen Phenotype of BALENTL 13-Repeated Testing* 
Transplan- 
tation gen- 
eration and 
suhline$ 
Tumor cell source 
Ly 1,2  Ly 2.2  TL  Thy 1,2 
CT  IF  ABS  CT  IF  ABS  CT  ABS  CT  ABS 
3-S  Ascites  >95  15 
(C 16)  (C 12) 
Mesenterie  >95  25 
lymph node  (C <i0)  (C <i0) 
4-A  Ascites  85  <5  <10 
(C <I0)  (C <5)  (C <I0) 
Solid peritoneal  78  51  31 
tumor mass  (C <15)  (C <15)  (C <17) 
4-S  Aseites  >95  +  4§  - 
(>1)  (<1) 
5-S  Ascites  90  10  12 
(C <5)  (C <5)  tC <I0) 
12-S  Solid peritoneal  >90  +  <5  - 
tumor mass 
17-A  Aseitas  >95  <1 
34 
(C  <5) 
18 
(C <5) 
+/<1011 
+15711 
*sora were used as described in  Table III and tests were performed as detailed in the text. C controls are indicated in parentheses below the 
test results. This tumor was consistently Ig  (<5%)  when tested by IF at generations 4, 12, and 17. 
~rhe number indicates the passage generation; the letters S and A indicate whether the line was initially  passed from the primary solid 
tumor in the chest cavity (S), or from the peritoneal ascites cells of the primary tumor (A). 
§No large tumor cells positive. 
IIAKR tumors (Thy  1.1 +) used for control absorptions did not decrease  the CT on A/J thymus cells in either case. 
TABLE V 
Ly Antigen Phenotype BALENTL 5-Repeated  Testing* 
Anti-Ly 1.2  Anti-Ly 2.2  Anti-TL  Anti-Thy 1.2 
Trans- 
plantation  Tumor cell  ABS 
source  ABS  ABS  ABS  ABS 
generation  CT  IF  IF on B6  CT  IF  IF  on B6  CT  IF  CT on  CT on A  CT  CT on A 
BALB 
2  SC  28  >90  >95 
3  SC  21  11  >90  >95  >95  80 
6  SC  15  -/>90  80  +•<5  64  +/<15  -/>90  >90  +t<5 
15  ASC  15  (+)§  39  >95  >95  >95  76 
15  SC  (+)§  >95  >95  >95  >95 
17  ASC  22  <10  -/>90  50  >95  +/<5  >95  >95  +/<15  -/82  54  +/<5 
17  IP Solid  20  <10  37  >95  >95  >95  85 
*Sera were similar to those described in Table II and tests were performed  as described in the text. This tumor was consistently Ig  (<5%) 
each time it was tested by IF. 
SMost of these positive cells were smaller than the typical tumor cell. 
§Although these cells appeared slightly positive the typical dot pattern of IF with anti-Ly was not observed with these cells.  Since this 
tumor appears  to have some  viral-related specificities, this positive result may be  an  artifact.  A  subsequent generation tested by 
absorption was negative for Ly 1.2. 
Discussion 
We have used three methods for testing the Ly and TL phenotype of T-cell 
tumors of BALB/c and AKR mice and two methods for detecting Thy 1 antigen. 
In  11  of the  13  tumors  either  Ly  1  or  Ly  2  antigen  is  expressed  at a  level 
comparable  to  Ly  antigen  expression  in  the  thymus  and  the  tumors  are 
"negative"  for the other Ly antigen.  Absorption and C-dependent cytotoxicity 
have indicated no more than a  minor background  (probably  normal host cell 
contamination) of positive cells for one of the Ly antigens: IF has indicated that 
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cannot eliminate the possibility that the phenotypic expression is below the 
level  of sensitivity of our tests,  for the  "negative" Ly antigen.  Nor  can we 
eliminate  the  possibility  that  the  minor  population  of small  Ly  1+2  +  cells 
present in the in vivo passaged tumors are stem cells for large tumor cells with 
restricted Ly phenotype. This is unlikely in view of preliminary observations 
which have indicated a lack of small positive cells among cells of established in 
vitro lines of these tumors.3 Therefore we conclude that there is preferential but 
not necessarily exclusive expression of either Ly 1 or Ly 2 on most tumors of 
these strains. 
It  is  remarkable that  so  many of the  thymic tumors  described  here  are 
"differentiated" for Ly  1  or  Ly 2  since  nearly all  thymus cells  express both 
antigens.  Partial  lysis  and  sequential  lysis  experiments  (2,  4)  have  distin- 
guished four subclasses of normal peripheral T cells with phenotypes indicated 
as follows: Ly 1+2+; Ly 1+2-;  Ly 1-2+;  Ly 1-2-.  Thus these tumors may reflect 
(a)  neoplastic  induction of a  partially differentiated thymus cell or alterna- 
tively,  (b)  neoplastic conversion of a  peripheral T  cell which returns to the 
thymus  to  produce  a  tumor.  The  first  possibility  is  more  likely  since  the 
majority of the BALB tumors are TL  +. 
TL antigen is expressed on thymus cells and on tumors of presumed T-cell 
origin but has not been found on peripheral T cells (20). Since some tumors are 
Ly 1+2 -4 or Ly 1-2 + and also TL  ÷, the presence of TL on these tumors might 
represent the derepression of a  tumor-specific TL antigen after differentiation 
has restricted the surface phenotype to either Ly 1  ÷ or Ly 2  ÷.  Although the 
BALB/c tumors have not been tested for all of the TL specificities, it appears 
that most of these tumors express more than the normal BALB/c thymus TL.2 
specificity. However, if the TL  + phenotype is simply the result of derepression 
of tumor-specific TL,  it is peculiar that the majority of these tumors (9 of 10) 
derived from a  TL.2 + strain  (BALB/c) are TL  ÷ tumors while the majority of 
tumors in  AKR,  a  TL-  strain  are TL-  (20,  30).  Thus the proportion  of TL  ÷ 
tumors reflects the TL genotype of the target for leukemogenesis. 
The normal differentiation process may involve the restriction of Ly before 
the differentiative loss of TL.  The tumor phenotype might indicate that the 
target  cell  for  leukemogenesis  is  a  partially  differentiated  thymocyte.  In 
spontaneous leukemogenesis of AKR mice (31,  32),  radiation leukemogenesis 
and  RadLV  virus-induced  leukemogenesis in  B6  mice  (31) the  preleukemic 
thymus becomes populated with cells expressing a low Thy 1, high H-2 antigen 
phenotype. Such a phenotype is characteristic of peripheral T cells rather than 
thymocytes which normally are high Thy 1, low H-2 cells. The tumors presented 
here were also characteristically less susceptible to lysis with anti-Thy 1 and C. 
Thus the target cell  population  for thymic leukemogenesis may represent a 
normally minor thymus cell population  which has reduced Thy 1 expression 
quantitatively and at least in part is differentiated for Ly antigen expression. 
Since a  subpopulation of thymocytes, capable of synergy in graft-versus-host 
s  Kim  et al. Manuscript in preparation. 
4  Preliminary examination of  3 (BALB/c × DBA/2)F~ tumor transplantation lines suggests that 
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reactions,  are  eliminated with  anti-TL  serum  (33), there may indeed be  a 
normal phenotypic counterpart to the type of cell observed in these tumors. 
Thus, we may have to re-examine the model of normal T-cell differentiation 
(16,  34)  which proposes  that  normal  thymocytes lose  the  potential  for TL 
expression before the differentiation of subpopulations restricted for Ly 1 or Ly 
2, and before the acquisition of the capacity to react specifically with antigens. 
In addition the following model of T-cell differentiation should be considered: 
TL  ÷ Ly 123 -~ Ly 123 
TL  ÷Ly123--~TL  ÷Lyl  -*Lyl 
TL  ÷Ly23  -~Ly23. 
An alternative explanation for the high proportion of TL  ÷ tumors exists: the 
anti-TL serum used in these tests may detect Qa-2  or T-cell differentiation 
antigens  related to  TL  by  genetic proximity on  chromosome 17  (35). This 
question is still under investigation. 
The stability of the phenotype over several generations and the finding of 
tumors with either the Ly 1  + or Ly 2+ phenotype supports the concept that these 
tumors represent states of T-cell differentiation. The stability further indicates 
that these antigens are not subject to modulation during transplantation of 
these tumor lines, but rather that the restricted Ly surface phenotype is an 
intrinsic property of these T-cell tumors. 
Although there appears to be a predominance of BALB/c lymphomas with the 
Ly 1-2  + phenotype, this is not true of AKR lymphomas. The Ly phenotype may 
depend on the method of tumor induction, the strain of mice used, or it may 
simply reflect a  sampling error due to the relatively small number of tumors 
tested from these strains. Eight of the BALB/c primary T-cell tumors presented 
as thymic tumors with or without evidence of generalized spread of  the leukemic 
process, while three tumors, each with a different Ly phenotype, BALENTL 9, 
13,  and  14,  arose  as  generalized T-cell leukemias possibly  originating from 
peripheralized T lymphocytes. 
Tumors have been described which subserve functions such as suppression 
(36), or autoaggression (37, 38), the Ly phenotype of those tumors may corre- 
spond with previously described phenotypes of normal functional immune cells. 
Since there is no exclusion of either of the restricted Ly phenotypes in these 
tumors, we find no support for the concept that all T-cell lymphomas will ex- 
press the Ly phenotypes described for normal killer and suppressor or normal 
helper cells.  However, individual tumor lines with such phenotypes may ex- 
press appropriate functions under particular experimental conditions. 
Beside the advantage of obtaining homogeneous populations with functional 
activity,  these  tumors  have  other  obvious  uses.  In  general,  tumors  with 
restricted Ly phenotypes may be useful as immunogens. BALENTL 13 has been 
used to produce anti-Ly 1.2 serum (F-W. Shen, personal communication). Since 
tumor  tissue  can  be  obtained  in  large  amounts,  and  with  the  apparent 
restriction of the Ly antigen these tumors will be invaluable as a  source for 
biochemical preparation of the antigen. Finally, the satisfactory description and 
availability of tumors such as these as models for T  cells may enable us to 
expand our knowledge of the cellular aspects of the immune response as much B.  J.  MATHIESON,  P.  S.  CAMPBELL,  M.  POTTER,  AND  R.  ASOFSKY  1277 
as plasmacytomas  have  enabled  investigators  to expand  our knowledge of B 
cells and antibody in immune responses. 
Summary 
Transplanted  lymphomas,  most of thymic  origin,  induced  in  BALB/c mice 
with  1-ethyl-l-nitrosourea  (ENU)  and  transplanted  spontaneously  occurring 
lymphomas  of AKR  mice  were  examined  for  the  expression  of the  T-cell 
antigens Ly, TL, and Thy 1 by using three serological methods. Most (11 of 13) 
of the Thy 1  + and/or TL  + tumors,  i.e.,  T-cell tumors,  expressed high levels of 
either Ly 1 or Ly 2 antigen, but not both. Thus most thymic lymphocytic tumors 
expressed restricted  Ly phenotypes comparable  to phenotypes previously de- 
scribed for functional peripheral T cells. Because tumor phenotypes were stable 
over  a  number  of transplant  generations,  they therefore  appeared  to  be an 
intrinsic property of the specific tumors. The majority of the BALB/c lymphomas 
were  Ly  1-  2  + and  also  positive  with  anti-TL  antiserum.  This  predominant 
phenotype on the BALB/c tumors may be related to either the mode of tumor 
induction  or  to  the  mouse  strain,  but  since  the  restricted  Ly  pattern  was 
observed both in BALB/c and AKR tumors,  the phenotypic restriction itself is 
not a  consequence of either of these factors. Tumor induction by ENU per se is 
not responsible for Ly or TL antigen expression since several non-T-cell BALB/ 
c tumors, also induced by ENU, did not express either Ly or TL antigens. 
Data presented here suggest that the target cell for leukemogenesis may be a 
partially differentiated thymus cell. The restricted expression of Ly antigens on 
differentiating  thymus  cells to either  the  Ly 1  + (Ly 1  1' ) or Ly 2  + (Ly 2  1') 
phenotype may occur before the loss of TL antigen. 
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